These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16636870)

  • 1. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
    van Giersbergen PL; Dingemanse J
    Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusion.
    van Giersbergen PL; Dingemanse J
    Clin Drug Investig; 2007; 27(11):797-802. PubMed ID: 17914898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of severe renal impairment on the pharmacokinetics of clazosentan.
    Bruderer S; Sasu B; Tsvitbaum N; Dingemanse J
    J Clin Pharmacol; 2011 Mar; 51(3):413-21. PubMed ID: 20926750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan.
    Juif PE; Dingemanse J; Voors-Pette C; Ufer M
    AAPS J; 2020 Aug; 22(5):103. PubMed ID: 32748293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.
    Bruderer S; Detishin V; Tsvitbaum N; Dingemanse J
    Br J Clin Pharmacol; 2011 Jan; 71(1):52-60. PubMed ID: 21143501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.
    Henrich A; Juif PE; Dingemanse J; Krause A
    J Pharmacokinet Pharmacodyn; 2021 Apr; 48(2):213-224. PubMed ID: 33389549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo pharmacokinetic characteristics of clazosentan, an intravenous endothelin receptor antagonist, in humans.
    van Giersbergen PL; Treiber A; Dingemanse J
    Int J Clin Pharmacol Ther; 2009 Mar; 47(3):169-77. PubMed ID: 19281726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of ethnic origin and sex on the pharmacokinetics of clazosentan.
    van Giersbergen PL; Gunawardena KA; Dingemanse J
    J Clin Pharmacol; 2007 Nov; 47(11):1374-80. PubMed ID: 17906281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.
    Dingemanse J; Clozel M; van Giersbergen PL
    Br J Clin Pharmacol; 2002 Apr; 53(4):355-62. PubMed ID: 11966665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist.
    Dingemanse J; Clozel M; van Giersbergen PL
    J Cardiovasc Pharmacol; 2002 Jun; 39(6):795-802. PubMed ID: 12021573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.
    Fujimura M; Joo JY; Kim JS; Hatta M; Yokoyama Y; Tominaga T
    Cerebrovasc Dis; 2017; 44(1-2):59-67. PubMed ID: 28463833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan.
    Juif PE; Voors-Pette C; Ufer M; Dogterom P; Dingemanse J
    Clin Transl Sci; 2019 Sep; 12(5):440-444. PubMed ID: 31004470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.
    Volz AK; Dingemanse J; Krause A; Lehr T
    Pharm Res; 2019 Dec; 37(1):2. PubMed ID: 31823033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage.
    Zisowsky J; Fuseau E; Bruderer S; Krause A; Dingemanse J
    Eur J Clin Pharmacol; 2014 Apr; 70(4):409-19. PubMed ID: 24458541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.
    Barth M; Capelle HH; Münch E; Thomé C; Fiedler F; Schmiedek P; Vajkoczy P
    Acta Neurochir (Wien); 2007; 149(9):911-8; discussion 918. PubMed ID: 17700991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different Doses of Clazosentan for Aneurismal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials.
    Rong WL; Xiao X; Zhao JL; Yang XW; Hu ZL; Li MH
    Am J Ther; 2018; 25(6):e652-e660. PubMed ID: 26752653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of severe renal impairment on the pharmacokinetics and tolerability of the parenteral endothelin antagonist tezosentan.
    van Giersbergen PL; Dingemanse J
    Int J Clin Pharmacol Ther; 2003 Jun; 41(6):261-6. PubMed ID: 12816178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
    Macdonald RL; Kassell NF; Mayer S; Ruefenacht D; Schmiedek P; Weidauer S; Frey A; Roux S; Pasqualin A;
    Stroke; 2008 Nov; 39(11):3015-21. PubMed ID: 18688013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.
    Vajkoczy P; Meyer B; Weidauer S; Raabe A; Thome C; Ringel F; Breu V; Schmiedek P
    J Neurosurg; 2005 Jul; 103(1):9-17. PubMed ID: 16121967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.
    Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Nowbakht P; Roux S; Kassell N
    Stroke; 2012 Jun; 43(6):1463-9. PubMed ID: 22403047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.